Myeloid sarcoma of the skull base: A case report and systematic literature review.
Acute myeloid leukemia
Chloroma
Myeloid sarcoma
Parasellar
Skull base
Journal
Surgical neurology international
ISSN: 2229-5097
Titre abrégé: Surg Neurol Int
Pays: United States
ID NLM: 101535836
Informations de publication
Date de publication:
2022
2022
Historique:
received:
15
03
2022
accepted:
02
05
2022
entrez:
8
6
2022
pubmed:
9
6
2022
medline:
9
6
2022
Statut:
epublish
Résumé
Myeloid sarcoma (MS), or chloroma, is a rare extramedullary malignant tumor that consists of undifferentiated granulocytic cells, and it is most commonly associated with acute myeloid leukemia (AML). Intracranial MS accounts for 0.4% of MS cases, and involvement of the skull base and visual dysfunction is rarely reported. However, the optimal treatment and response to treatment of skull base MS in the presence of visual symptoms is unknown. A 30-year-old male with a history of AML presented with rapidly progressive vision loss and a sellar and parasellar mass with bilateral cavernous sinus and optic nerve encasement. The patient underwent endoscopic endonasal transsphenoidal biopsy revealing intracranial MS. He was treated postoperatively with high-dose intravenous and intrathecal cytarabine and had complete restoration of his vision by postoperative day 11. A systematic review of the literature identified six cases of skull base MS, five of whom presenting with visual symptoms. All patients underwent systemic chemotherapy with cytarabine and/or cyclophosphamide, with infrequent use of intrathecal chemotherapy or radiation. Those with reported visual outcomes were diagnosed 4 months or longer after symptom onset and demonstrated no visual improvement with treatment. Skull base MS is a rare disease entity with a high prevalence of visual dysfunction. Our patient's complete disappearance of intracranial disease and resolution of visual symptoms with systemic and intrathecal chemotherapy highlight the importance of timely diagnosis and appropriate treatment without a need for direct surgical decompression.
Sections du résumé
Background
UNASSIGNED
Myeloid sarcoma (MS), or chloroma, is a rare extramedullary malignant tumor that consists of undifferentiated granulocytic cells, and it is most commonly associated with acute myeloid leukemia (AML). Intracranial MS accounts for 0.4% of MS cases, and involvement of the skull base and visual dysfunction is rarely reported. However, the optimal treatment and response to treatment of skull base MS in the presence of visual symptoms is unknown.
Case Description
UNASSIGNED
A 30-year-old male with a history of AML presented with rapidly progressive vision loss and a sellar and parasellar mass with bilateral cavernous sinus and optic nerve encasement. The patient underwent endoscopic endonasal transsphenoidal biopsy revealing intracranial MS. He was treated postoperatively with high-dose intravenous and intrathecal cytarabine and had complete restoration of his vision by postoperative day 11. A systematic review of the literature identified six cases of skull base MS, five of whom presenting with visual symptoms. All patients underwent systemic chemotherapy with cytarabine and/or cyclophosphamide, with infrequent use of intrathecal chemotherapy or radiation. Those with reported visual outcomes were diagnosed 4 months or longer after symptom onset and demonstrated no visual improvement with treatment.
Conclusion
UNASSIGNED
Skull base MS is a rare disease entity with a high prevalence of visual dysfunction. Our patient's complete disappearance of intracranial disease and resolution of visual symptoms with systemic and intrathecal chemotherapy highlight the importance of timely diagnosis and appropriate treatment without a need for direct surgical decompression.
Identifiants
pubmed: 35673665
doi: 10.25259/SNI_255_2022
pii: 10.25259/SNI_255_2022
pmc: PMC9168333
doi:
Types de publication
Case Reports
Langues
eng
Pagination
220Informations de copyright
Copyright: © 2022 Surgical Neurology International.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Clin Neuropathol. 2012 Sep-Oct;31(5):369-73
pubmed: 22541780
Br J Haematol. 2008 Sep;142(5):681
pubmed: 18477037
World Neurosurg. 2019 Oct;130:110-114
pubmed: 31284058
Leukemia. 2007 Feb;21(2):340-50
pubmed: 17170724
Blood. 2011 Oct 6;118(14):3785-93
pubmed: 21795742
Ann Intern Med. 1995 Sep 1;123(5):351-3
pubmed: 7625623
Biomed Pharmacother. 2013 Feb;67(1):72-7
pubmed: 23218987
J Clin Med. 2015 May 21;4(5):1102-12
pubmed: 26239467
Pediatr Radiol. 1988;18(5):369-72
pubmed: 3050842
Am J Clin Pathol. 2009 Sep;132(3):426-37
pubmed: 19687319
Am J Blood Res. 2013 Dec 18;3(4):265-70
pubmed: 24396704
Tohoku J Exp Med. 2018;246(2):141-146
pubmed: 30369515
Stem Cells. 2014 Jun;32(6):1380-9
pubmed: 24497003
Blood Res. 2020 Mar;55(1):10-16
pubmed: 32269970
Ther Adv Hematol. 2011 Oct;2(5):309-16
pubmed: 23556098
Diagn Pathol. 2007 Oct 31;2:42
pubmed: 17974004
Br J Radiol. 2017 Jul;90(1075):20160710
pubmed: 28445074
World Neurosurg. 2021 Apr;148:29-37
pubmed: 33444829
Onco Targets Ther. 2020 Jun 25;13:6085-6092
pubmed: 32612369
Neuropathology. 2014 Apr;34(2):179-84
pubmed: 24118374